


REMARKS

Currently claims 1-21 are pending. Applicants amend claims 1-4, 7-8, 11-12, 14-15, 17, and 20 to correct typographic errors and to reduce the filing fee by, *inter alia*, removing multiple dependency. Claims 16 and 18-19 are cancelled as being in a form inappropriate to US practice. Claims 22-24 are added. Accordingly, claims 1-15, 17, and 20-24 are presented for examination. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,


John L. Lemanowicz
Attorney for Applicant
Registration No. 37,380

Date: 8/10/06
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8247
Facsimile: 919-483-7988